Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.



  • What is known about idarucizumab for dabigatran reversal?
  • What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention?
  • What is the role of topical tranexamic acid to prevent postsurgical bleeding from major cardiovascular and orthopedic procedures?


  • What are the key features of the most recent guidelines for the management of patients with atrial fibrillation?
  • What recent evidence describes the comparative safety and efficacy of bivalirudin and heparins in patients undergoing percutaneous coronary intervention?
  • Can the intravenous formulation of vitamin K be administered orally?


  • Can angiotensin receptor blockers (ARBs) be administered to patients who develop angioedema on angiotensin-converting enzyme inhibitor (ACEI) therapy?
  • What are the data to support the use of ethanol lock therapy to decrease catheter-related infections in pediatric patients?
  • What is the cross-reactivity of penicillins and carbapenems in a patient with a penicillin allergy?


  • Can intermittent proton pump inhibitor dosing be used in acute upper gastrointestinal bleeding?
  • What data support the safety and efficacy of the intravenous P2Y12 inhibitor cangrelor?
  • Is the recently updated cholesterol guideline cost-effective and better at identifying at-risk patients than the previous ATP III guideline?


  • How will fusion technology for factor concentrates change prophylaxis strategies in the management of hemophilia A and B?
  • How should allergic reactions to local anesthetics be managed?
  • What is the efficacy and safety evidence for Zarxio (filgrastim-sndz), the first biosimilar approved in the United States?


  • What are the new recommendations for 13-valent pneumococcal conjugate vaccine (PCV13) in older adults?
  • What is the safety information available on the use of NOACs in patients with renal impairment?
  • How should patients receiving new oral anticoagulants be managed prior to planned surgical procedures?


  • What is the evidence to support twice-daily dosing of insulin glargine?
  • What is the rationale and significance of the FDA’s new guidance for abuse-deterrent opioids?
  • What should healthcare providers know about PCSK9 inhibitors, the new class of cholesterol-lowering medications?


  • What evidence supports the efficacy of the new antibiotic, ceftazidime/avibactam (Avycaz)?
  • What should healthcare providers know about the recent measles outbreak in the United States?
  • What are the current recommendations for managing patients initiating non-VKA oral anticoagulants (NOACs) after receiving thrombolytic therapies for pulmonary embolism?


  • What drugs should be avoided in myasthenia gravis?
  • Is normal saline or heparin preferred as a catheter flush solution?
  • Should warfarin be resumed after gastrointestinal bleeding, and if so – when?


  • What are the new guidelines for the pharmacological management of obesity?
  • What information is available on the use of peramivir for treatment of influenza?
  • What data supports the use of new oral anticoagulants in special populations (hepatic impairment, obesity, pregnancy, lactation, and pediatrics)?


  • What are the new recommendations for direct-acting antivirals for treatment of hepatitis C virus?
  • What is the Evidence for Use of Inhaled Epoprostenol?
  • What vaccines should be administered to adult, splenectomized, patients?


  • What is the Evidence for Use of Bronchodilators in Bronchiolitis?
  • What are Current Recommendations for Treatment of Drug Extravasation?
  • Is Vancomycin Therapy with Targeted Troughs Between 15 and 20 mg/L Associated with an Increased Risk of Nephrotoxicity?